MD Opp/Regs

The Montgomery Family Medicine Residency program is seeking a Board Certified Family Medicine physician to join the faculty.  For more information, please click the link below.

 Montgomery Family Medicine Residency Program

Homewood Family Medicine is urgently looking for a dynamic FP interested in working in a small, demographically diverse growing practice that includes everything from pediatrics to geriatrics in a full range of services in downtown Birmingham.  The position is permanent full or part-time, using an EMR and electronic billing system, with only outpatient medicine; that will share night call and office hours, with hospital supplementation of income and benefits. 

Send resume to:  [email protected].

Family physician wanted for rural program at  UAB Huntsville campus

Primary care physician to direct pipeline programs to recruit medical students from rural Alabama for the UAB School of Medicine Rural Medicine Program (RMP). Responsibilities include working with college and university career counselors about medical student recruitment; making presentations to pre-medical students about rural medical programs and medical school admissions; directing pre-medical summer internship for college students;  directing academic programs for current RMP students;  training primary care physicians to serve as advisors, mentors and teachers for pre-med and enrolled medical students; serving on admissions committee of the UAB School of Medicine; representing the RMP in statewide rural health efforts, such as AHEC. Statewide travel required as well as limited out-of-state travel. The position is based at the Huntsville Regional Medical Campus. This can be a full-time or part-time position and can include clinical duties based on individual interest. It is possible clinical duties can be arranged to maintain licensing. Send CV to Paula Cothren, UAB School of Medicine, Huntsville Regional Medical Campus, 301 Governors Dr. SW, Room 313, Huntsville AL 35801.


 Birmingham, Alabama

Focus-MD, a network of medical clinics devoted to improving the quality of care for adults, children and adolescents with ADHD and related disorders is seeking a BC/BE Family Physician or Internist to join our Birmingham office. No call and no weekends.  We are devoted to evidence based medicine and provide further clinical training and FDA cleared objective testing. Our EHR is customized to the work we do and physician friendly so you aren’t charting at night or on the weekend.  Our staff is well trained and efficient.  If you are ready to have time to spend with patients, interested in practicing quality medicine that truly changes lives and would like to have more time for your personal life we want to talk to you.

Visit our website at focus—

Contact James Wiley, MD, FAAP   [email protected]



Alabama’s Target - 95%






For more information click link below



Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)


October 12, 2012 / 61(40);816-819

On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants (Table). PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23, Merck & Co. Inc.), the vaccine currently recommended for these groups of adults (1). The evidence for the benefits and risk of PCV13 vaccination of adults with immunocompromising conditions was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and designated as a Category A recommendation (2,3). This report outlines the new ACIP recommendations for PCV13 use; explains the recommendations for the use of PCV13 and PPSV23 among adults with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants; and summarizes the evidence considered by ACIP to make its recommendations.

Epidemiology of Pneumococcal Infection in Immunocompromised Adults

Streptococcus pneumoniae (pneumococcus) remains a leading cause of serious illness, including bacteremia, meningitis, and pneumonia among adults in the United States. An estimated 4,000 deaths occur in the United States each year because of S. pneumoniae, primarily among adults (4). The incidence of invasive disease ranges from 3.8 per 100,000 among persons aged 18–34 years to 36.4 per 100,000 among those aged ≥65 years (4). Adults with certain medical conditions also are at increased risk for invasive pneumococcal disease (IPD). For adults aged 18–64 years with hematologic cancer, the rate of IPD in 2010 was 186 per 100,000, and for persons with human immunodeficiency virus (HIV) the rate was 173 per 100,000 (CDC, unpublished data, 2012). The disease rates for adults in these groups can be more than 20 times those for adults without high-risk medical conditions.

PCV13 has been used for children since 2010, when it replaced an earlier version targeting seven serotypes (PCV7; Prevnar, Pfizer) that had been in use since 2000. The routine use of PCV7 in infants and young children resulted in significant reductions in IPD caused by vaccine serotypes in children, and because of indirect effects, also in adults. Rates of IPD caused by vaccine serotypes in adults aged 18–64 years without HIV decreased from six cases to one case per 100,000 during 2000–2007. However, even after indirect effects of the pediatric immunization had been realized fully, the incidence of IPD caused by the serotypes included in PCV7 remained high in HIV-infected persons aged 18–64 years at 64 cases per 100,000 persons with acquired immunodeficiency syndrome (AIDS) (5). Moreover, 50% of IPD cases among immunocompromised adults in 2010 were caused by serotypes contained in PCV13; an additional 21% were caused by serotypes only contained in PPSV23 (CDC, unpublished data, 2011).

PCV13 Vaccine in Adults

PCV13 was licensed by the Food and Drug Administration (FDA) for prevention of IPD and otitis media in infants and young children in February 2010, supplanting PCV7 (6). PCV13 is identical in formulation for the seven common serotypes in PCV7, but it includes six additional antigens. One dose of PCV13 is recommended by ACIP for children aged 6–18 years with high-risk conditions such as functional or anatomic asplenia, immunocompromising conditions, cochlear implants, or CSF leaks. In December 2011, FDA licensed PCV13 for prevention of pneumonia and IPD in adults aged ≥50 years (7). The license for adult use was granted under FDA's accelerated approval pathway, which allows the agency to approve products for serious or life-threatening diseases on the basis of early evidence of a product's effectiveness that is reasonably likely to predict clinical benefit. Approval of PCV13 for adults was based on immunogenicity studies that compared antibody responses to PCV13 with antibody responses to PPSV23 (7).

In two randomized, multicenter immunogenicity studies conducted in the United States and Europe, immunocompetent adults aged ≥50 years received a single dose of PCV13 or PPSV23 (8). In adults aged 60–64 years and aged >70 years, PCV13 elicited opsonophagocytic activity (OPA) geometric mean antibody titers (GMTs) that were comparable with, or higher than, responses elicited by PPSV23. OPA GMTs elicited by PCV13 in adults aged 50–59 years for all 13 serotypes were comparable with the corresponding GMTs elicited by administration of PCV13 in adults aged 60–64 years. Persons who received PPSV23 as the initial study dose had lower opsonophagocytic antibody responses after subsequent administration of a PCV13 dose 1 year later than those who had received PCV13 as the initial dose (8). Data on the immunogenicity of PCV13 in immunocompromised adults are not available.

Safety of PCV13 was evaluated in approximately 6,000 PPSV23-naïve and PPSV23-experienced adults aged ≥50 years (8). Overall incidence of serious adverse events reported within 1 month of an initial study dose was <2% for both vaccines, with no significant differences between treatment groups. Common adverse reactions reported with PCV13 were pain, redness, and swelling at the injection site; limitation of movement of the injected arm; fatigue; and headache (8). Safety studies presented for licensure did not enroll immunocompromised subjects.

Although clinical trial data are not yet available for PCV13, a randomized, controlled trial of PCV7 efficacy among 496 HIV-infected adults in Malawi demonstrated vaccine efficacy of 75% (95% confidence interval = 29%–92%) in preventing IPD (9). The study population differed from the general U.S. HIV-infected population, however, in that all participants had survived a previous episode of IPD, only 13% were on antiretrovirals, and the all-cause mortality rate was >25%. The number of serious adverse events within 14 days after vaccination was significantly lower (three versus 17; p=0.002) in the vaccine group (248 persons) than in the placebo group (248 persons), whereas minor adverse events were significantly more common in the vaccine group (41 versus 13; p=0.003) (9).

Four studies of PCV7 immunogenicity involving 699 HIV-infected subjects, all with CD4 counts of >200 cells/µL, were conducted in the United States and Europe. Antibody response to a single dose of PCV7 was comparable with PPSV23 for the serotypes evaluated, at all times studied (10–13). When PPSV23 and PCV7 were administered in series, greater immune response was demonstrated when PCV7 was given first (8,11). None of the studies were designed to evaluate the optimal interval between doses; however, in another study, no evidence of blunting of an immune response to PCV7 was observed when a dose of PPSV23 was given 5 years (range: 3.5–6.6 years) before a dose of PCV7 (14).

PPSV23 Vaccine

PPSV23 contains 12 of the serotypes included in PCV13, plus 11 additional serotypes. PPSV23 is recommended for prevention of IPD among all adults aged ≥65 years, and for adults at high risk aged 19–64 years (1,3). Although conflicting evidence regarding PPSV23 efficacy in HIV-infected adults has been published (15,16), the GRADE evaluation reviewed by ACIP concluded that potential benefits from PPSV23 use in this population outweigh any potential harms. Given the high burden of IPD caused by serotypes in PPSV23 but not in PCV13, broader protection might be provided through use of both pneumococcal vaccines.

The current ACIP PPSV23 recommendations call for vaccination of adults at high risk aged 19–64 years at the time of diagnosis of the high-risk condition. A one-time revaccination dose of PPSV23 is recommended 5 years after the first dose for persons with functional or anatomic asplenia and for immunocompromised persons (Table). All adults are eligible for a dose of PPSV23 at age 65 years, regardless of previous PPSV23 vaccination; however, a minimum interval of 5 years between PPSV23 doses should be maintained (1).


A cost-effectiveness analysis was performed using a lifetime cohort model of an implemented vaccine program wherein persons with selected immunocompromising conditions were immunized with PCV13 at the time of diagnosis and then followed current PPSV23 vaccination guidelines starting 1 year later. PCV13 vaccine efficacy against IPD and pneumonia (used as a proxy for effectiveness in the model) was 75% and 13%, respectively, for persons with HIV/AIDS and persons requiring dialysis, and 25% and 0%, respectively, for persons with hematologic cancer and for organ transplant recipients. Using the current costs of PCV13, PPSV23, and administration, the modeled program resulted in a cost saving of $7,600,000, added 1,360 quality-adjusted life years, and averted 57 cases of IPD (CDC, unpublished data, 2012). These savings accrued largely as a result of protection among patients on dialysis and those with HIV/AIDS. Heterogeneity across risk groups was driven by differences in pneumococcal serotypes causing disease and assumed vaccine efficacy in each subgroup. The model was sensitive to assumptions about vaccine efficacy, whereby increased estimation of PCV13 efficacy led to increases in cost-effectiveness.

ACIP Recommendations for PCV13 and PPSV23 Use

Adults with specified immunocompromising conditions who are eligible for pneumococcal vaccine should be vaccinated with PCV13 during their next pneumococcal vaccination opportunity.

Pneumococcal vaccine-naïve persons. ACIP recommends that adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later (Table). Subsequent doses of PPSV23 should follow current PPSV23 recommendations for adults at high risk. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19–64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. Additionally, those who received PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years, or later if at least 5 years have elapsed since their previous PPSV23 dose.

Previous vaccination with PPSV23. Adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, who previously have received ≥1 doses of PPSV23 should be given a PCV13 dose ≥1 year after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23.

Reported by

Nancy M. Bennett, MD, Advisory Committee on Immunization Practices Pneumococcal Work Group. Cynthia G. Whitney, MD, Matt Moore, MD, Tamara Pilishvili, MPH, Respiratory Diseases Br, Div of Bacterial Diseases, National Center for Immunization and Respiratory Diseases; Kathleen L. Dooling, MD, EIS Officer, CDC. Corresponding contributor: Tamara Pilishvili, [email protected], 404-639-3585.


Members of the Advisory Committee on Immunization Practices; member roster for July 2011–June 2012 available at


  1. CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010;59:1102–6.
  2. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ; ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171–6.
  3. CDC. ACIP GRADE tables, 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. Available at Accessed October 10, 2012.
  4. CDC. Active Bacterial Core surveillance report, Emerging Infections Program Network, Streptococcus pneumoniae, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at Accessed October 1, 2012.
  5. Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010;24:2253–62.
  6. CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59:258–61.
  7. Food and Drug Administration. FDA expands use of Prevnar 13 vaccine for people ages 50 and older. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at Web Site Icon. Accessed October 10, 2012.
  8. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at Adobe PDF fileExternal Web Site Icon. Accessed October 10, 2012.
  9. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362:812–22.
  10. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2002;20:545–53.
  11. Lesprit P, Pédrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007;21:2425–34.
  12. Peñaranda M, Payeras A, Cambra A, et al. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010;24:1226–8.
  13. Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010;202:1114–25.
  14. Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005;192:1801–5.
  15. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000;355:2106–11.
  16. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000;160:2633–8.

TABLE. Medical conditions or other indications for administration of 13-valent pneumococcal conjugate vaccine (PCV13), and indications for 23-valent pneumococcal polysaccharide vaccine (PPSV23) administration and revaccination for adults aged ≥19 years,* by risk group — Advisory Committee on Immunization Practices, United States, 2012

Risk group

Underlying medical condition





Revaccination 5 yrs after first dose

Immunocompetent persons

Chronic heart disease



Chronic lung disease§



Diabetes mellitus



Cerebrospinal fluid leak


Cochlear implant





Chronic liver disease, cirrhosis



Cigarette smoking



Persons with functional or anatomic asplenia

Sickle cell disease/other hemaglobinopathy

Congenital or acquired asplenia

Immunocompromised persons

Congenital or acquired immunodeficiency

Human immunodeficiency virus infection

Chronic renal failure

Nephrotic syndrome



Hodgkin disease

Generalized malignancy

Iatrogenic immunosuppression**

Solid organ transplant

Multiple myeloma

* All adults aged ≥65 years should receive a dose of PPSV23, regardless of previous history of vaccination with pneumococcal vaccine.

Including congestive heart failure and cardiomyopathies, excluding hypertension.

§ Including chronic obstructive pulmonary disease, emphysema, and asthma.

Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

** Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.


FDA Expands Use of Prevnar 13 Vaccine for Adults Aged 50 and Older: Prevnar 13, a pneumococcal 13-valent conjugate vaccine (which contains 13 different serotypes of the bacterium Streptococcus pneumoniae), was approved on December 30, 2011, by the U.S. Food and Drug Administration (FDA) for adults aged 50 years and older to prevent pneumonia and invasive disease caused by the bacterium.

Pneumococcal pneumonia, caused when the bacterium Streptococcus pneumoniae infects the lungs, is the most common disease caused by this bacterium in adults. When the bacterium invades parts of the body that are normally sterile, such as the blood or spinal fluid, the disease is considered “invasive.”

The new use for Prevnar 13 was approved under the agency's accelerated approval pathway, which allows for earlier approval of treatments for serious and life-threatening illnesses. The pathway allows for the demonstration of effectiveness of a vaccine using an immune marker that is reasonably likely to predict clinical benefit.

In randomized, multi-center studies in the United States and Europe, adults aged 50 and older received either Prevnar 13 or Pneumovax 23, a licensed pneumococcal vaccine currently approved for use among adults 65 years of age or older and younger adults with chronic medical conditions. The studies showed that for the 12 serotypes common to both vaccines, Prevnar 13 induced antibody levels that were either comparable to or higher than the levels induced by Pneumovax 23.

The safety of Prevnar 13 was evaluated in about 6,000 adults aged 50 and older who received Prevnar 13 and who had and had not previously received Pneumovax 23. Common adverse reactions reported with Prevnar 13 were pain, redness, and swelling at the injection site, limitation of movement of the injected arm, fatigue, headache, chills, decreased appetite, generalized muscle pain, and joint pain. Similar reactions were observed in those who received Pneumovax 23.

Accelerated approval is granted on the condition that a clinical trial is conducted during the post-approval marketing of the vaccine to verify the anticipated clinical benefit in adults 50 years of age and older. An additional trial in 85,000 adults aged 65 and older, with no previous history of receiving Pneumovax 23, is underway to confirm the clinical benefit of Prevnar 13 in the prevention of pneumococcal pneumonia.

Prevnar 13 is already approved for use in children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 different serotypes of Streptococcus pneumoniae and for the prevention of otitis media caused by seven of the serotypes of the bacterium.  


How Physicians Can Electronically Exchange in 2012


Alabama’s Health Information Exchange (HIE), called OneHealthRecord, is launching in April 2012 as a means for healthcare providers to exchange patient information electronically.  Is your practice ready to exchange?  The Alabama Academy of Family Physicians and the Alabama Chapter-American Academy of Pediatrics, through its Practice Management Association, are pleased to join forces to present this 60-minute webinar in order to meet meaningful use requirements and deliver more informed care.


This session, which is complementary benefit for AAFP and AL-AAP members, PMA members and family practice managers, features a presentation and Q&A with Dan Roach, MD, Alabama’s HIT Coordinator; Gary Parker, IT Project Director, Alabama’s OneHealthRecord, Alabama Medicaid Agency; and Kent Ogle, Client Program Director, Thomson-Reuters.  Participants will learn:


·         How Alabama’s OneHealthRecord will allow physicians to meet meaningful use criteria;

·         The methods available for a physician’s office to engage in electronic health information exchange;

·         How to evaluate the health information technology maturity level of your practice in order to begin exchanging


Simply click the link below and view the webinar, should you have questions please contact your AAFP staff.


Change in Credits Awarded in ABFM SAMS Courses

February 09, 2011

The ABFM recently submitted data to the AAFP indicating that the average time in which diplomates reported completing the Self-Assessment Modules (SAMs) is 11.84 hours. The AAFP awards Prescribed credit on an hour-for-hour basis, based on quarter-hour segments, for time spent in formal education. Therefore, the 2011 SAMs courses will be awarded 12 Prescribed credits. AAFP Accreditation Requirements for Enduring Material can be found on the AAFP website. Additional information about ABFM SAM Modules can be found on the ABFM website under "Maintenance of Certification, Part II."


If you have questions, please contact the ABFM, or Chris Hodges , AAFP CME Accreditation Specialist.



 - Moving Alabama Providers from Paper to Electronic Health Records


“This is an exciting opportunity for the providers in Alabama.  We understand that transitioning from paper to electronic records can be a daunting and expensive task.  Our job is to help make this a smoother and faster transition resulting in the potential for more efficient patient care.  This will ultimately translate to a better workflow for the providers and better quality of care for the patients.”


Dan Roach, MD

Project Director, ALREC;

Assistant Dean, COM Medical Informatics Education

Director Medical Informatics, USA CSHI

The University of South Alabama Center for Strategic Health Innovation (USA CSHI), representing a statewide consortium of partners and stakeholders, was recently awarded a cooperative agreement to serve as the Alabama Regional Extension Center, or ALREC. Partners and stakeholders include The University of South Alabama, Alabama Medicaid Agency, The University of Alabama at Birmingham, Auburn University, Alabama Hospital Association, Alabama Primary Healthcare Association, Alabama Academy of Family Physicians, Alabama Academy of Pediatrics, the JHD Group and Management and Medical Consulting Services, Inc. ALREC will serve as an advocate for Alabama physicians and deliver services to assist providers in moving from paper to electronic health records and in achieving Meaningful Use status.  

Membership in ALREC is open to all providers in Alabama and provides access to services such as group purchasing discounts, EHR adoption assistance, assistance with education and training, workflow analysis and project management, interfaces to HIEs and more.  ALREC will provide education and vendor neutral direct technical assistance to ensure that providers in Alabama will be eligible for Medicare and Medicaid incentive reimbursements.  Whether you already have an electronic health record in place or not, the comprehensive technical expertise available within ALREC will ensure your practice successfully implements EHR, meets Meaningful Use requirements, and receive incentives potentially up to $67,300 per provider.

Federal funding under the cooperative agreement is targeted to “Priority Primary Care Providers” (PPCPs), or providers in practices of 10 or less who specialize in primary care, family practice, obstetrics, gynecology, geriatrics, or internal medicine.  However, all providers who join ALREC will receive adoption and implementation services at significantly reduced rates.

To encourage enrollment of PPCPs, ALREC has agreed to waive membership fees for the first 1,000 PPCPs through April, 2011.  This is a unique opportunity for primary care providers in Alabama, so act now to ensure you are able to take advantage of the services offered by ALREC. 


For more information, please contact ALREC:


Alabama Regional Extension Center (ALREC)

307 University Blvd./TRP III, Suite 1100

Mobile, Alabama  36688

Phone:  (251) 414-8170

Fax:  (251) 414-8171